| Literature DB >> 31865177 |
Charlotte A Mintie1, Chandra K Singh1, Nihal Ahmad2.
Abstract
Skin is arguably the largest organ of the body and is continuously subjected to intrinsic, extrinsic, and environmental stresses. Therefore, skin developed elaborate mechanisms to maintain homeostasis, including antioxidant, antiinflammatory, and DNA damage repair capabilities. However, repeated and excessive stresses can overwhelm these systems, causing serious cutaneous damages, including skin carcinogenesis. Phytonutrients present in the diet possess a myriad of health-promoting effects by protecting skin from damaging free radicals as well as by other mechanisms. Although many chemoprotective phytonutrients have been shown to be efficacious individually, a combination of multiple agents could have synergistic response in curtailing or preventing cutaneous damages. Here, we discuss the benefits of natural amalgamation of phytonutrients in select fruits against skin damage including carcinogenesis. However, a majority of these studies have been done in preclinical models. Therefore, clinical studies are needed to determine the human relevance of the available preclinical data, especially in the human population who are at higher risk for skin cancers (e.g., organ transplant patients). In addition, detailed well-structured preclinical animal studies in the models of high-risk skin carcinogenesis could also be useful toward informing the design for human trials. Published by Elsevier Inc.Entities:
Year: 2019 PMID: 31865177 PMCID: PMC6926315 DOI: 10.1016/j.tranon.2019.10.014
Source DB: PubMed Journal: Transl Oncol ISSN: 1936-5233 Impact factor: 4.243
Figure 1Solar ultraviolet radiation and skin: Major wavelengths and their effects on the skin.
Figure 2Ultraviolet radiation and skin cancer: Steps involved in skin carcinogenesis.
In Vitro and In Vivo Studies to Assess the Effects of Fruits in Skin and Skin Conditions.
| Chemopreventive Constituents | Experimental Model | Dose of Chemopreventive Agents | Dose of Carcinogen | Reference |
|---|---|---|---|---|
| Grape (Burgund Mare) seed extract | HaCaT | 10 or 20 μg/ml | UVB (100 or 200 mJ/cm2) | [ |
| Black raspberry extract | JB6 C1 41 with AP-1 luciferase reporter | 50 μg/mL, 30 min prior | UVB (2 kJ/m2) | [ |
| Black raspberry extract | JB6 C1 41 with AP-1, or NF-κB, or p53 luciferase reporter | 25 μg/mL, 30 min prior | BPDE (2 μM) | [ |
| Black raspberry extract | JB6 C1 41 with AP-1, or VEGF luciferase reporter, or PI3K mutant | 25 μg/mL, 30 min prior | BPDE (2 μM) | [ |
| Blackberry (tropical highland) juice | NHEK | 1:300 or 1:500, 2 h prior, or immediately for 24 h | UVB (25 mJ/cm2) | [ |
| Blackberry (tropical highland) juice | Human reconstituted skin equivalent | Topical (10 μL), 2 h prior, or immediately for 24 h | UVB (25 mJ/cm2) | [ |
| Pomegranate fruit extract | NHEK | 10–40 μg/mL, 24 h prior | UVB (40 mJ/cm2) | [ |
| Pomegranate extract (POMx) | HaCaT | 10–40 μg/mL, 24 h prior | UVB (15 or 30 mJ/cm2) | [ |
| Pomegranate juice, oil, or extract | EpidermTM FT-200 reconstituted human skin | 1–2 μL, or 5–10 μg/0.1 ml/well, 1 h prior | UVB (60 mJ/cm2) | [ |
| Apple peel extract | JB6/AP/kB | 1:10 to 1:640, 2 h prior | TPA (20 nmol) or UVB (4 kJ/m2) | [ |
| Grape (Muscat Bailey) stem extract | BALB/c mice | Topical (1 mg in 0.2 ml propylene glycol), daily | UVB (120 mJ/cm2), 3× weekly for 1 month | [ |
| Grape (Campbell Early) stem extract | C57BL | Topical (50 mg/kg), daily, 1 week prior | UVB (120 mJ/cm2), 3× weekly for 3 weeks | [ |
| Y-grape juice or ethyl acetate extract | SENCAR | Topical (10 or 20 μL) single dose | TPA (1.7 nmol), single dose | [ |
| Y-grape juice or ethyl acetate extract | SENCAR | Topical (×2 or ×10), 2× weekly, 30 min prior, or oral, | DMBA initiation (2.5 mg/animal) and TPA promotion (1.7 nmol) for 20 weeks | [ |
| Grape seed proanthocyandins | SKH-1 hairless mice | Oral, | UVB (180 mJ/cm2) 3× weekly for 24 weeks | [ |
| Grape (Burgund Mare) seed extract | SKH-1 hairless mice | Topical, (4 mg/cm2), 30 min prior, single dose | UVB (240 mJ/cm2), single dose | [ |
| Grape (Burgund Mare) seed extract | SKH-1 hairless mice | Topical (2.5 or 4 mg/cm2), 30 min prior or post | UVB, (240 mJ/cm2), daily for 10 days | [ |
| Grape (red, green, black) powder | SKH-1 hairless mice | Oral, | UVB (180 mJ/cm2) 2× weekly for 28 weeks | [ |
| Grape (red, green, black) powder | SENCAR | Topical (1, 2, or 4 mg), 30 min post | DMBA (100 nmol), 2×/week (4 or 24 weeks) | [ |
| Powdered grape seed extract | SENCAR | Topical (1, 2, or 4 mg), 30 min post | DMBA (100 nmol), 2×/week for 4 weeks | [ |
| Grape (red, green, black) powder | SENCAR | Oral (1%, 2%, or 5% in AIN-93GA diet), 2 weeks prior | DMBA (100 nmol), 2× weekly for 12 or 24 weeks | [ |
| Black raspberry extract | SKH-1 hairless mice | Topical (500 μg), immediately post | UVB (2240 kJ/m2), 3× weekly for 25 weeks | [ |
| Black raspberry extract | SKH-1 hairless mice | Topical (500 μg), immediately post | UVB (2240 kJ/m2), single dose | [ |
| Blackberry extract | SKH-1 hairless mice | Topical (10% or 20%), one day prior | UVB (100 mJ/cm2), 3× weekly for 10 weeks | [ |
| Pomegranate fruit extract | CD-1 | Topical (2 mg), 30 min prior | TPA (3.2 nmol), single dose | [ |
| Pomegranate fruit extract | CD-1 | Topical (2 mg), prior to TPA | DMBA (50 nmol), TPA (3.2 nmol) 2× weekly for 30 weeks | [ |
| Pomegranate seed oil | CD-1 | Topical (5%), 1 h prior | DMBA (200 nmol), TPA (5 nmol) 2× weekly for 20 weeks | [ |
| Pomegranate fruit extract | SKH-1 hairless mice | Oral (0.2% in drinking water), 14 days prior | UVB (180 mJ/cm2), single dose | [ |
| Pomegranate fruit extract | SKH-1 hairless mice | Oral (0.2% in water), 14 days prior up to termination | UVB (180 mJ/cm2), 7 doses on alternating days | [ |
| Apple peel extract | AP-1 luciferase reporter transgenic mice (C57BL/6 × DBA2) | Oral, | TPA (5 μg) or UVB (10 kJ/m2), single dose on fourth day of APE | [ |
| Apple peel extract | AP-1-luciferase reporter transgenic mice (C57BL/6 × DBA2) | Oral, | DMBA (400 nmol), TPA (17 nmol) 14 days later, 2× weekly for 20 weeks | [ |
| Tangerine tomato powder | SKH-1 hairless mice | Oral, (10% in AIN-93GA diet), 10 weeks prior | UVB (2240 J/m2), single dose at week 10 | [ |
| Tangerine or red tomato powder | SKH-1 hairless mice | Oral, | UVB (2240 J/m2), 3× weekly, weeks 11 through 20 | [ |
Clinical Trials to Assess the Effects of Whole Fruit on Varying Diseases and Health.
| Clinical Trials | |||||
|---|---|---|---|---|---|
| Grape | Pomegranate | Apple | Berry | Tomato | |
| Active, not recruiting | 16 | 4 | 8 | 8 | 6 |
| Completed | 123 | 62 | 132 | 48 | 49 |
| Enrolling by invitation | 1 | 1 | 3 | 0 | 0 |
| Not yet recruiting | 10 | 2 | 9 | 5 | 4 |
| Recruiting | 27 | 4 | 30 | 12 | 7 |
| Unknown status | 21 | 15 | 15 | 6 | 4 |
| Withdrawn | 1 | 2 | 5 | 2 | 3 |
| Terminated | 1 | 0 | 4 | 0 | 1 |
| Total | 200 | 90 | 206 | 81 | 74 |
Figure 3Molecular mechanisms of whole fruit products involved in the prevention of carcinogenesis process related to skin cancer. Arrows and red text indicate upregulation and/or activation, and lines with a blunt end and green text indicate downregulation and/or inhibition.